|
Prophase Labs Inc
PRPH's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Prophase Labs Inc 's sales fell
by -87.76 % in II. Quarter 2024 from the same quarter a year ago.
Ranking at No. 2788
Major Pharmaceutical Preparations industry recorded
growth of revenues by 5.15 %
Prophase Labs Inc net loss increased from $-3 millions, to $-6 millions in II. Quarter 2024,
• More on PRPH's Growth
|
|
Prophase Labs Inc realized a net loss in trailing twelve months.
Prophase Labs Inc realized cash reduction of $ -0.08 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 2.35.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.48.
• More on PRPH's Valuation
|
|
|
|
|
Prophase Labs Inc realized net loss in trailing twelve months.
Prophase Labs Inc realized cash outflow of $ -0.08per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 2.35.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.48.
Prophase Labs Inc Price to Book Ratio is at 0.94 lower than Industry Avg. of 83. and higher than S&P 500 Avg. of 0
• More on PRPH's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com